Otavio Berwanger to Anticoagulants
This is a "connection" page, showing publications Otavio Berwanger has written about Anticoagulants.
Connection Strength
0.265
-
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 06 12; 397(10291):2253-2263.
Score: 0.049
-
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J. 2021 08; 238:1-11.
Score: 0.049
-
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 04 18; 380(16):1509-1524.
Score: 0.042
-
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018 08; 202:89-96.
Score: 0.039
-
Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). Am Heart J. 2017 Oct; 192:38-47.
Score: 0.038
-
Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. Anesth Analg. 2017 07; 125(1):162-169.
Score: 0.038
-
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017 Oct 14; 390(10104):1737-1746.
Score: 0.010